Quantcast
Last updated on April 21, 2014 at 8:55 EDT

Latest Amphastar Pharmaceuticals Inc. Stories

2012-07-18 02:26:18

Primatene® Mist Critical For Millions of Asthmatics Lacking Health Insurance; All Manufacturer's Net Profits from Sales of Primatene® Mist will be Donated to Charity WASHINGTON, July 18, 2012 /PRNewswire-USNewswire/ -- The makers of Primatene® Mist have launched a campaign to put the over-the-counter inhaler back on the market in the United States, after it was banned because it contains a small amount of chlorofluorocarbons (CFCs), leaving millions of asthmatics...

2012-01-26 10:26:00

PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States Court of Appeals for the Federal Circuit has granted Watson and Amphastar Pharmaceuticals, Inc's request for a stay of the preliminary injunction preventing the companies from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX®. The Federal Circuit's Order does not represent a final decision...

2011-10-28 16:29:00

PARSIPPANY, N.J., Oct. 28, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX®. The Company said...

2011-10-08 18:22:00

PARSIPPANY, N.J., Oct. 8, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Massachusetts has granted a request by Momenta Pharmaceuticals, Inc. and Sandoz Inc. for a temporary restraining order (TRO) preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection product, a generic equivalent to Sanofi-aventis' LOVENOX®. The...

2011-10-07 17:37:00

PARSIPPANY, N.J., Oct. 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Massachusetts has granted a request by Momenta Pharmaceuticals, Inc. and Sandoz Inc. for a temporary restraining order (TRO) preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection product, a generic equivalent to Sanofi-aventis' LOVENOX®. The...

2011-09-22 08:11:00

PARSIPPANY, N.J., Sept. 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, Inc. and Watson on September 21, 2011 in the United States District Court for the District of Massachusetts. The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the U.S. retail pharmacy channel, infringes...

2011-09-19 15:02:00

PARSIPPANY, N.J., Sept. 19, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration ("FDA") approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 100mg/mL and 150mg/mL strengths. Enoxaparin Sodium Injection is the generic equivalent to Sanofi-aventis' LOVENOX®, and is a low molecular weight heparin indicated in the...